A Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial Evaluating the Efficacy and Safety of QLS12010 Capsules in Adult Participants With Moderate-to-Severe Atopic Dermatitis
Latest Information Update: 23 Jan 2026
At a glance
- Drugs QLS 12010 (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors Qilu Pharmaceutical
Most Recent Events
- 23 Jan 2026 New trial record